Outcomes With Transcatheter Mitral Valve Repair in the United States: An STS/ACC TVT Registry Report.

BACKGROUND Post-market surveillance is needed to evaluate the real-world clinical effectiveness and safety of U.S. Food and Drug Administration-approved devices. OBJECTIVES The authors examined the commercial experience with transcatheter mitral valve repair for the treatment of mitral regurgitation. METHODS Data from the Society of Thoracic Surgery/American College of Cardiology Transcatheter Valve Therapy Registry on patients commercially treated with transcatheter mitral valve repair were analyzed. The study population consisted of 2,952 patients treated at 145 hospitals between November 2013 and September 2015. In 1,867 patients, data were linked to patient-specific Centers for Medicare and Medicaid Services administrative claims for analyses. RESULTS The median age was 82 years (55.8% men), with a median Society of Thoracic Surgery predicted risk of mortality of 6.1% (interquartile range: 3.7% to 9.9%) and 9.2% (interquartile range: 6.0% to 14.1%) for mitral repair and replacement, respectively. Overall, in-hospital mortality was 2.7%. Acute procedure success occurred in 91.8%. Among the patients with Centers for Medicare and Medicaid Services linkage data, the mortality at 30 days and at 1 year was 5.2% and 25.8%, respectively, and repeat hospitalization for heart failure at 1 year occurred in 20.2%. Variables associated with mortality or rehospitalization for heart failure after multivariate adjustment were increasing age, lower baseline left ventricular ejection fraction, worse post-procedural mitral regurgitation, moderate or severe lung disease, dialysis, and severe tricuspid regurgitation. CONCLUSIONS Our findings demonstrate that commercial transcatheter mitral valve repair is being performed in the United States with acute effectiveness and safety. Our findings may help determine which patients have favorable long-term outcomes with this therapy.

[1]  D. Capodanno,et al.  One- and twelve-month safety and efficacy outcomes of patients undergoing edge-to-edge percutaneous mitral valve repair (from the GRASP Registry). , 2013, The American journal of cardiology.

[2]  N. Smedira,et al.  Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. , 2014, Journal of the American College of Cardiology.

[3]  Philippe Ravaud,et al.  What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? , 2007, European heart journal.

[4]  A. Kastrati,et al.  Acute and Midterm Outcome After MitraClip Therapy in Patients With Severe Mitral Regurgitation and Left Ventricular Dysfunction. , 2015, The American journal of cardiology.

[5]  M. Mack,et al.  Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. , 2014, Journal of the American College of Cardiology.

[6]  M. Enriquez-Sarano,et al.  Quantitative Determinants of the Outcome of Asymptomatic Mitral Regurgitation , 2005 .

[7]  M. De Carlo,et al.  Comparison of Percutaneous Mitral Valve Repair Versus Conservative Treatment in Severe Functional Mitral Regurgitation. , 2016, The American journal of cardiology.

[8]  Danica Marinac-Dabic,et al.  The STS-ACC transcatheter valve therapy national registry: a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies. , 2013, Journal of the American College of Cardiology.

[9]  M. Enriquez-Sarano,et al.  Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. , 2008, JACC. Cardiovascular imaging.

[10]  M. Post,et al.  Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients. , 2014, JACC. Cardiovascular interventions.

[11]  C. Di Mario,et al.  Immediate and 12-Month Outcomes of Ischemic Versus Nonischemic Functional Mitral Regurgitation in Patients Treated With MitraClip (from the 2011 to 2012 Pilot Sentinel Registry of Percutaneous Edge-To-Edge Mitral Valve Repair of the European Society of Cardiology). , 2017, The American journal of cardiology.

[12]  S. Blankenberg,et al.  Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. , 2014, Journal of the American College of Cardiology.

[13]  D. Capodanno,et al.  Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry. , 2015, JACC. Cardiovascular interventions.

[14]  John D. Carroll,et al.  Clinical outcomes at 1 year following transcatheter aortic valve replacement. , 2015, JAMA.

[15]  R A Levine,et al.  Prevalence and clinical outcome of mitral-valve prolapse. , 1999, The New England journal of medicine.

[16]  M. Enriquez-Sarano,et al.  Echocardiographic Prediction of Survival After Surgical Correction of Organic Mitral Regurgitation , 1994, Circulation.

[17]  S. Blankenberg,et al.  Transcatheter Mitral Valve Repair in Surgical High-Risk Patients: Gender-Specific Acute and Long-Term Outcomes , 2016, BioMed research international.

[18]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[19]  Allan Schwartz,et al.  Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. , 2005, Journal of the American College of Cardiology.

[20]  O. Alfieri,et al.  Mitraclip therapy and surgical mitral repair in patients with moderate to severe left ventricular failure causing functional mitral regurgitation: a single-centre experience. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[21]  M. Mack,et al.  Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. , 2014, Journal of the American College of Cardiology.

[22]  S. Kapadia,et al.  Initial Experience With Commercial Transcatheter Mitral Valve Repair in the United States. , 2016, Journal of the American College of Cardiology.

[23]  Nancy M Albert,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, The Journal of thoracic and cardiovascular surgery.

[24]  Pascal Vranckx,et al.  Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. , 2011, Journal of the American College of Cardiology.

[25]  M. Mack,et al.  A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are Not Candidates for Surgery. , 2015, JACC. Cardiovascular interventions.

[26]  M. Mack,et al.  5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial , 2015, The Lancet.

[27]  D. Adams,et al.  Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. , 2016, Journal of the American College of Cardiology.

[28]  Thoralf M Sundt,et al.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[29]  P. Boekstegers,et al.  One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry , 2015, European heart journal.

[30]  M. Mack,et al.  Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. , 2015, Journal of the American College of Cardiology.

[31]  J. Hausleiter,et al.  Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. , 2013, Journal of the American College of Cardiology.